Transurethral plasmakinetic resection of prostate in high-risk benign prostatic hyperplasia patients: a multicenter prospective study

Objective To investigate the clinical efficacy of transurethral plasmakinetic resection of prostate (TUPKP) in treating high-risk benign prostatic hyperplasia (BPH) patients. Methods A prospective multicenter study design was employed. Patients with high-risk BPH treated with TUPKP were enrolled in the urology departments of 20 hospitals nationwide according to the inclusion and exclusion criteria. Relevant data regarding patient baseline, perioperative period, and 3-month postoperative follow-up were analyzed to evaluate efficacy and safety. Results From September 2016 to December 2018, a total of 229 high-risk BPH patients were enrolled. Compared to baseline at the 3-month follow-up, the change in the International Prostate Symptom Score was -17.28[95%CI(-18.02, -16.54)], the change in maximum urinary flow rate was 5.61[95%CI(0.68, 10.54)]mL·s-1, the change in residual urine volume was -84.50 [95%CI(-96.49, -72.51)] mL, and the change in quality of life score was -3.24[95%CI(-3.42, -3.06)],all showing signi